Grail
Pioneering multi-cancer early detection through ground-breaking solutions, achieving ISO 13485 Certification for robust development and manufacture of regulated medical products.
Grail is a trailblazing biotech firm specializing in multi-cancer early detection (MCED) through innovative solutions, including the flagship product Galleri®. They have obtained ISO 13485 Certification and plan to initiate the REACH study for Galleri® to evaluate its clinical impact, showcasing their commitment to regulatory standards and advancing MCED technology. Recognized as a top biopharma company by BioSpace, Grail has presented at notable industry events such as ISPOREurope.
About Grail
Grail is a pioneering biotech company that develops and provides ground-breaking solutions in the field of multi-cancer early detection (MCED). They have recently achieved ISO 13485 Certification, which underscores their dedication to implementing robust policies and procedures for the development and manufacture of regulated medical products. Grail's flagship product, Galleri®, is at the forefront of this innovation, with plans to initiate the REACH study to evaluate its clinical impact. The prospective, multi-center study aims to assess the added value of Galleri® in addition to currently recommended cancer screenings. Grail has presented their research on real-world implications of MCED at prominent industry events such as ISPOREurope and has been recognized as a top biopharma company by BioSpace.
